Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
CER TEK bio
AddedFeb 18, 2024
UpdatedJun 18, 2026
CER TEK bio

CER TEK bio

Cer Tek Bio: Innovating in medical treatments, disease management, and vaccines, with a focus on gastrointestinal disorders. Committed to improving global health.

HQ
Los Angeles, CA, US
Founded
1972
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to revolutionize healthcare, CER TEK bio focuses on medical innovations, disease management, and vaccine development, particularly targeting gastrointestinal disorders. Their core vision is to improve global health by creating accessible and effective medical solutions. Notably, their groundbreaking vaccine technology eliminates the need for intramuscular injections and booster shots, aiming to enhance safety and ease of administration.

CER TEK bio has garnered attention for its ethical approach and commitment to safety. The organization has made significant strides in improving lives through its innovative products. While specific notable affiliated people and investors are not mentioned, the company's impact on global health through its novel vaccine technologies and disease management solutions is evident. Their contributions are paving the way for healthier populations and better quality of life worldwide.

CER TEK bio - Similar Companies

TheraJect logo

TheraJect

Centivax logo

Centivax

centivax.com

X-Vax Technology logo

X-Vax Technology

VitriVax logo

VitriVax

vitrivaxbio.com

Med-Tek logo

Med-Tek

med-tek.com

Concord Medical Technology logo

Concord Medical Technology

Nano Cures logo

Nano Cures

nanocures.com

Petri Bio logo

Petri Bio

petribio.com

Cerus logo

Cerus

CelgenTek logo

CelgenTek

Jurata Thin Film logo

Jurata Thin Film

juratatf.com

Ceramedix Holding logo

Ceramedix Holding

ceramedix.com

ArkeaBio logo

ArkeaBio

arkeabio.com

Innovac Therapeutics logo

Innovac Therapeutics

innovactx.com

Transcera logo

Transcera

CER TEK bio - Quick Facts

Who are CER TEK bio's competitors?

Companies similar to CER TEK bio include TheraJect, Centivax, X-Vax Technology and VitriVax.

When was CER TEK bio founded?

CER TEK bio was founded in 1972.

Where is CER TEK bio's headquarters located?

CER TEK bio's headquarters is located in Los Angeles, CA, US.

When was CER TEK bio's last funding round?

CER TEK bio's most recent funding round was for $800k (USD) in July 2023.

How much has CER TEK bio raised to-date?

As of Jul 7, 2023, CER TEK bio has raised a total of $800k (USD).

How many employees does CER TEK bio have?

CER TEK bio has 5 employees as of Feb 4, 2024.

CER TEK bio - Classification

Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Consumers
  • Enterprise
Main Product
  • Medical
  • Vaccines
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software